secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115303
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025
--------------------------------------------------------------------------------

- Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.
- Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.
- License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.
- Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.
- Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/0001104659-24-115303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/tm2427679d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer